AstraZeneca gains 2% on DGCA approval for Dapagliflozin tablet

Dapagliflozin film-coated tablet 10mg is an additional indication in adults for the treatment of heart failure with reduced ejection fraction.

Jul 06, 2020 10:07 IST India Infoline News Service

AstraZeneca Pharma India on Monday soared by nearly 2% by opening at an intraday high of Rs3570 per piece on Sensex. Investors had upside bias on the company's stock after it bagged the Drugs Controller General of India (DGCA) approval for Dapagliflozin film-coated tablet 10mg.

AstraZeneca informed exchanges that it has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) for Dapagliflozin.

"The receipt of this Import and Market permission paves way for launch of Dapagliflozin film-coated tablet 10mg in India, subject to the receipt of related statutory approvals and licenses," said AstraZeneca in a filing.

The company's Dapagliflozin film-coated tablet 10mg is an additional indication in adults for the treatment of heart failure with reduced ejection fraction.

At around 10.30 am, the company's stock was trading at Rs3526.65 per piece up by 0.42% on Sensex.

In the previous closing, the stock stood at Rs3511.95 per piece.

Related Story